Industry Information

Update October 10, 2021

690 million yuan! Shanghai Pharmaceuticals introduces a new type of antacid drug

On October 9, Shanghai Pharmaceuticals issued an announcement that its wholly-owned subsidiaries, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd. (hereinafter referred to as "Shangyao Xinyi") and...

Update October 09, 2021

Haosen Pharmaceutical's Class 1 new drug Peihua Xihippocampal peptide injection has been declared and marketed

Recently, Jiangsu Hausen Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Hausen Pharmaceutical" or the "Company") independently developed a Class 1 new drug Peihua Xihippocampal peptide...

Update October 08, 2021

Rising star-Trop2, the target of antibody-conjugated drugs (ADC)

Recently, Kelun Pharmaceutical announced the Phase I clinical data of SKB264 at the CSCO annual meeting. As of April 28, 2021, 17 patients have received at least one efficacy evaluation. The total...

Update September 30, 2021

The global market will reach 96 billion U.S. dollars. Where is the Chinese clinical trial industry?

Along with economic development and the intensification of aging, people's health awareness is increasing, and the demand for pharmaceutical products continues to increase. According to the analysis...

Update September 29, 2021

Hisun Biologics ``Infliximab'' biosimilar drug approved for marketing

On September 28, Hisun Pharmaceuticals announced that Hisun Bio, a wholly-owned subsidiary of Borui Bio, received the "Drug Registration Certificate" for "Infliximab for Injection" approved and...

Update September 28, 2021

The existence of We-too is reasonable, and it is the only way for the development of Chinese medicine.

After the trough caused by the storm of drug registration and verification in 2006, the declaration of domestic innovative drugs began to grow slowly from 2009; After the implementation of the new...

Update September 24, 2021

EP2 antagonists were discovered ten years ago. What breakthroughs have been made in the treatment of inflammation?

Currently, non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen, and naproxen play an important role in the clinical treatment of anti-inflammatory. However, NSAIDs are...

Update September 23, 2021

Preliminary Pharmaceuticals and Celsion reached a second cooperation to develop DNA vaccines

On September 22, Hainan Puli Pharmaceutical Co., Ltd. announced that it had recently signed a framework cooperation agreement on DNA vaccines with Celsion Corporation of the US biopharmaceutical....

Update September 22, 2021

Hengrui Medicine's application for the treatment of HER2-positive breast cancer with pyrrotinib has been accepted

According to the data of Yaozhi, Hengrui Medicine's application for the new indications of pyrrotinib maleate tablets was accepted by CDE. According to the press release issued by Hengrui Medicine,...

Update September 18, 2021

Luye Pharma and ESTEVE reach an agreement to commercialize a new Alzheimer's disease drug in Spain

On September 16, Luye Pharmaceutical Group announced that its subsidiary, Luye Pharmaceuticals (Switzerland), has reached an agreement with Esteve Pharmaceuticals, S.A. (ESTEVE), granting the latter...